Invitae (NVTA) Stock Price, News & Analysis

Company Overview

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $0.0003 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.02 to $0.02
• Volume: 75 shs
• Average Volume: 23.72 million shs
• Market Capitalization: $80,103.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Invitae Stock Analysis - MarketRank™

Invitae scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Invitae.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Invitae are expected to grow in the coming year, from ($1.05) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Invitae has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NVTA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Invitae does not currently pay a dividend.

Dividend Growth

Invitae does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.13

Short Interest

There is no current short interest data available for NVTA.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for NVTA on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Invitae to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Invitae insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.74% of the stock of Invitae is held by insiders.

Percentage Held by Institutions

61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NVTA Stock Analysis - Frequently Asked Questions

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) issued its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.04. The company's quarterly revenue was down 5.1% compared to the same quarter last year.

When did Invitae IPO?

Invitae (NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Invitae investors own include NVIDIA (NVDA), Block (SQ), Tesla (TSLA), Meta Platforms (META), CrowdStrike (CRWD), Teladoc Health (TDOC) and PayPal (PYPL).

Company Calendar

• Last Earnings: 5/09/2023
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: N/A
• Current Symbol: NYSE:NVTA
• CUSIP: N/A
• CIK: 1501134
• Web: www.invitae.com
• Phone: (628) 213-3369
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,106,290,000.00
• Net Margins: -299.14%
• Pretax Margin: -301.93%
• Return on Equity: -6,100.71%
• Return on Assets: -19.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $481.58 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 267,010,000
• Free Float: 284,373,000
• Market Cap: $80,103.00
• Optionable: Optionable
• Beta: 1.59